Drug reference

ibalizumab

Entry Inhibitor · Antiretroviral

Entry InhibitorAntiretroviral

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

Ibalizumab is a humanized monoclonal antibody that binds to the CD4 extracellular domain 2, causing steric hindrance of a conformational change in the gp120-CD4 complex necessary for HIV fusion and entry. It does not inhibit gp120 attachment to CD4.

Indications

heavily treatment-experienced adults with multidrug-resistant HIV-1 infection

Side effects

Common

diarrheadizzinessnausearash

Related guidelines

Antiretroviral therapy for HIV

NACO · Infectious Diseases · 2018

Skin and soft tissue infections

IDSA · Infectious Diseases · 2010

Hepatitis B — chronic infection

EASL · Gastroenterology · 2025

Urinary tract infection

EAU · Urology · 2024

Latent tuberculosis infection

RNTCP · Infectious Disease · 2023

Other Entry Inhibitor drugs

fostemsavir

0 brands

Ask House about ibalizumab

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team